Measles
Annex 17 Generating Consensus Sequences with Sequencher
Annex C 16: CDC Protocol for amplification and sequencing of measles virus MF-NCR from patient samples
The conclusions of the Global Measles and Rubella Strategic Plan 2012–2020 implementation midterm review highlighted the need to update protocols for guiding surveillance and outbreak investigation...
Workshop presentation
T. Cherian, D. Durrheim, W. Moss, W. Orenstein, H. Rees
Workshop presentation
Rudi Eggers (WHO), Jan Grevendonk (WHO), Elicah Kandinda Kamiji (MoH Zambia), Imran Mirza (UNICEF), Abigail Shefer (US CDC)
Plenary presentation
Narendra Arora (INCLEN), Peter Figueroa (U of the West Indies), Jim Goodson (US CDC), Shabir Madhi (NICD, South Africa), Peter Strebel (WHO), Kim Thompson (Kids Risk)
This implementation guidance summarizes and builds on current global recommendations and programmatic considerations for establishing and/or strengthening platforms for the vaccination of health...
Nationally representative household survey that provides data for wide range of monitoring and impact evaluation indicators in the areas of population, health and nutrition.
The WHO website provides a list of certain diseases for which vaccines are available, and a list of some pathogens for which vaccines and/or monoclonal antibodies (mAbs) are in development. For each...
Communities at risk of non- and under-vaccination are often characterized by poverty, lack of access to health care and other basic services, civil/political unrest, poor sanitation practices,...
The Consortium aims to deliver a more sustainable, efficent, and transparent approach to generating disease burden and vaccine impact estimates. It works on aggregating the estimates across a...
Les vaccins contre la rougeole et la rubéole sont sûrs et efficaces, mais la couverture équitable, en particulier pour la deuxième dose de vaccin contenant la rougeole (MCV2), est bien...
Le COVID exigeant des sessions de plus petite taille, il est plus important que jamais de réduire la taille des flacons de vaccins pour mieux les adapter à la taille des sessions.
Cette...
Measles and rubella vaccines are safe and effective, however, achieving equitable coverage, particularly for the second dose of measles containing vaccine (MCV2) is well below the 95% target of...
The specific objectives of the review were to: i) provide a candid estimation or review of the
progress towards achieving the regional goal by 2023; ii) assess the quality of implementation...
Comparison of measles and rubella IgM EIA kits
Invitrogen Real Time PCR Template: Rubella with Diluted ROX
Real-time RT-PCR Assays for the Detection of Measles Virus (MeV) N Gene RNA and Human RNase P mRNA (a cellular reference gene) using the ABI 7500 Real-Time Thermocycler
Real-time RT-PCR Assays for the Detection of Rubella Virus RNA and Human RNase P mRNA using the ABI 7500 Real-time Thermocycler
RT-PCR protocol for rubella genotyping using nested set amplifications Enzyme kit: Qiagen One-Step RT-PCR
Measles or rubella virus isolation and preparation of virus stocks
Creating a Table and Chart to Describe Genotyping Data
Directions for finding and using the MeaNS distinct sequence ID
The following protocol provides recommendations for the purification of DNA fragments from positive PCR reactions.
List of Abbreviation, taken from the (Manual for the Laboratory-based Surveillance of Measles, Rubella, and Congenital Rubella Syndrome
Annex B4a. Job Aid for Serion ELISA Classic Measles/rubella Virus IgM
Annex B3. EuroImmun protocol for rubella IgM ELISA
Annex B2c. EuroImmun IgM ELISA Manual Calculation Worksheet with built-in calculations
Annex B2b. EuroImmun IgM ELISA Manual Calculation Worksheet
Annex B2. EuroImmun protocol for measles IgM ELISA
Annex E7. Protocol for measles genotyping with M13 primers (CDC)
Annex E1. Real-time RT-PCR for measles vaccine strains
Annex D2. Supplemental information for optimal laboratory design
Annex C10. Agarose gel electrophoresis with measles and rubella synthetic positive controls
Annex C9. Phylogenetic analysis (MEGA v7 or X) of measles and rubella sequences assembled using Genestudio
Annex C8. Measles & rubella sequence assembly (editing) using GeneStudio
Annex C7. Rubella sequence analysis for genotyping using MEGA v5.05
Annex C6. Measles sequence analysis for genotyping using MEGA v6.06
Annex C5a. Rubella sequencing worksheet for Annex C5
Annex C5. Rubella sequencing protocol for genotyping (CDC)
Annex C4a. Measles sequencing worksheet for Annex C4
Annex C4. Measles sequencing protocol for genotyping (CDC)
Annex C3. Protocol for rubella genotyping RT-PCR, Invitrogen Superscript III (CDC)
Annex C2. Protocol for rubella genotyping RT-PCR, Qiagen (CDC)
Annex C1a. Worksheet for Annex C1 (Qiagen and Invitrogen Superscript)
Annex B11c. Worksheet (triplicate wells) for Annex B11
Annex B11b. Plate layout (duplicate wells) for Annex B11
Annex B9. Confirmation of rubella virus in culture by IFA and ICA
Annex B7. Propagation and maintenance of Vero/hSLAM cell culture (CDC)
Annex B4c. Serion IgM ELISA Worksheet with built-in calculations
Annex B4b. Serion IgM ELISA Manual Calculation Worksheet
Annex A1. Measles and rubella laboratory request form
This report addresses the epidemiological aspects and feasibility of measles and rubella eradication and the potential resource requirements in response to the request of the Director-General at the...
Short message service (SMS) reminders coupled with a small monetary incentive conditioned on prompt vaccination have been shown to improve first-dose measles-containing vaccine (MCV1) uptake. We...
This study estimated the economic cost of treating measles in children under-5 in Bangladesh from the caregiver, government, and societal perspectives.
From January 2017 through July 2018, the DPCP conducted implementation research using quantitative and qualitative methods in Central and Luapula provinces in Zambia. The country was selected to...
The WHO initiative, Market Information for Access to Vaccines (MI4A) produces vaccine-specific market studies, analyzing global demand and supply prospects for individual vaccines. The studies...
The impact of COVID-19-related disruption to vaccination programs varies between infections and countries. Planning and implementation of campaigns should consider country and infection-specific...
There is very limited evidence about the economic cost of measles in low-income countries. We estimated the cost of treating measles in Uganda from a societal perspective.
Measles and rubella vaccines are safe and effective, however, achieving equitable coverage, particularly for the second dose of measles containing vaccine (MCV2) is well below the 95% target of...
This document was developed for public health professionals and laboratory scientists in Member States to support their decisions about conducting serosurveys in the context of achieving goals for...
This document outlines practical clinical care interventions and infection prevention and control measures required to reduce the high levels of morbidity and mortality that can occur during measles...
This executive summary details the key findings from the 5-dose MCV research in Zambia: improved coverage, reduced wastage, no cold chain constraints, and healthcare workers were more willing to open...
This case study describes the impact of changing to 5-dose measles containing vaccine in Zambia with improved coverage, lower wastage rate and no cold chain constraints.
This Facts Sheet informs of the availability of Measles vaccine and combined Measles-Rubella (MR) vaccine in both a 10-dose vial and a 5-dose vial presentations through (or via) UNICEF procurement....
SIA readiness assessment tool: dashboard and excel sheets
The World Health Organization (WHO) measles programmatic risk assessment tool was developed to help national programmes to identify areas not meeting measles programmatic targets, and based on the...